Aclaris Therapeutics Inc
NASDAQ:ACRS
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| US |
|
Aclaris Therapeutics Inc
NASDAQ:ACRS
|
339.1m USD |
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
987.9B USD |
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
596.5B USD |
Loading...
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
293B CHF |
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
249.7B CHF |
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
240.5B GBP |
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
307.4B USD |
Loading...
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD |
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK |
Loading...
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
156.9B USD |
Loading...
|
|
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
125.6B USD |
Loading...
|
Market Distribution
| Min | -24 813% |
| 30th Percentile | 28.9% |
| Median | 43% |
| 70th Percentile | 60.5% |
| Max | 10 905 714.3% |
Other Profitability Ratios
Aclaris Therapeutics Inc
Glance View
Aclaris Therapeutics, Inc. operates as a dermatologist-led biopharmaceutical company, which engages in identifying, developing, and commercializing novel drugs to address the needs in medical and aesthetic dermatology and immunology. The company is headquartered in Wayne, Pennsylvania and currently employs 75 full-time employees. The company went IPO on 2015-10-07. The firm is focused on leveraging its experience in drug discovery and development and kinase inhibition to develop small molecule therapies to help people impacted immuno-inflammatory conditions. The Company’s drug candidates are Zunsemetinib (ATI-450), ATI-1777 and ATI-2138. The Company’s ATI-450, an investigational oral, small molecule selective MK2 inhibitor compound, for the treatment of rheumatoid arthritis. Its ATI-1777, an investigational topical soft-JAK 1/3 inhibitor compound, for the treatment of atopic dermatitis. The firm is engaged in developing ATI-2138, its investigational oral inhibitor compound, as a potential treatment for T-cell mediated autoimmune diseases. The company is also developing oral gut biased JAK inhibitors, as a potential treatment for inflammatory bowel disease.
See Also
Gross Margin is calculated by dividing the Gross Profit by the Revenue.
The current Gross Margin for Aclaris Therapeutics Inc is 4%, which is below its 3-year median of 34.8%.
Over the last 3 years, Aclaris Therapeutics Inc’s Gross Margin has decreased from 50.7% to 4%. During this period, it reached a low of 4% on Sep 30, 2025 and a high of 59.8% on Dec 31, 2022.
